MX2010004875A - Derivados de tiazol y metodos para utilizarlos. - Google Patents

Derivados de tiazol y metodos para utilizarlos.

Info

Publication number
MX2010004875A
MX2010004875A MX2010004875A MX2010004875A MX2010004875A MX 2010004875 A MX2010004875 A MX 2010004875A MX 2010004875 A MX2010004875 A MX 2010004875A MX 2010004875 A MX2010004875 A MX 2010004875A MX 2010004875 A MX2010004875 A MX 2010004875A
Authority
MX
Mexico
Prior art keywords
thiazole derivatives
protein kinase
kinase inhibitors
disorder
proliferative disorder
Prior art date
Application number
MX2010004875A
Other languages
English (en)
Inventor
Marc A Labroli
M Arshad Siddiqui
Lianyun Zhao
Timothy J Guzi
Panduranga Adulla P Reddy
Tzu T Wong
Shuyi Tang
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010004875A publication Critical patent/MX2010004875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con novedosos Derivados de tiazol, con composiciones que comprenden los Derivados de Tiazol, y con métodos para usar los Derivados de Tiazol para el tratamiento o prevención de un trastorno proliferativo, un trastorno antiproliferativo, inflamación, artritis, un trastorno del sistema nervioso central, una enfermedad cardiovascular, alopecia, una enfermedad neuronal, una lesión isquémica, una infección viral, una infección fúngica o un trastorno relacionado con la actividad de una proteína quinasa.
MX2010004875A 2007-10-29 2008-10-27 Derivados de tiazol y metodos para utilizarlos. MX2010004875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98332707P 2007-10-29 2007-10-29
PCT/US2008/081316 WO2009058728A1 (en) 2007-10-29 2008-10-27 Thiazole derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2010004875A true MX2010004875A (es) 2010-05-19

Family

ID=40251710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004875A MX2010004875A (es) 2007-10-29 2008-10-27 Derivados de tiazol y metodos para utilizarlos.

Country Status (11)

Country Link
US (1) US8476278B2 (es)
EP (1) EP2212318B1 (es)
JP (1) JP5230035B2 (es)
CN (1) CN101910165A (es)
AR (1) AR069083A1 (es)
CA (1) CA2703978A1 (es)
CL (1) CL2008003200A1 (es)
MX (1) MX2010004875A (es)
PE (1) PE20091347A1 (es)
TW (1) TW200930715A (es)
WO (1) WO2009058728A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227605B2 (en) * 2006-10-31 2012-07-24 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
WO2009058729A2 (en) * 2007-10-29 2009-05-07 Schering Corporation Thiazole carboxamide derivatives and their to treat cancer
WO2011025706A2 (en) * 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US8435976B2 (en) * 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
CN102625807B (zh) * 2009-09-08 2016-03-09 霍夫曼-拉罗奇有限公司 4-取代的吡啶-3-基-甲酰胺化合物和使用方法
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
WO2011124580A1 (en) 2010-04-07 2011-10-13 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
JP2013530199A (ja) * 2010-07-06 2013-07-25 ノバルティス アーゲー キナーゼ阻害剤として有用な環状エーテル化合物
CN102924446B (zh) * 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
MY169268A (en) 2012-03-30 2019-03-20 Rhizen Pharmaceuticals S A Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2021237111A1 (en) * 2020-05-21 2021-11-25 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
CN113069451B (zh) * 2021-04-02 2022-08-09 苏州大学 一种吡咯-2-磺酰胺化合物的制备方法及其在制备抗肿瘤药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495582B1 (en) 2000-09-15 2002-12-17 Vertex Pharmaceuticals Incorporated Isoxazole compositions useful as inhibitors of ERK
FR2856685B1 (fr) * 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
WO2007123269A1 (ja) * 2006-04-19 2007-11-01 Astellas Pharma Inc. アゾールカルボキサミド誘導体
US8227605B2 (en) * 2006-10-31 2012-07-24 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
WO2008054702A1 (en) * 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
US8318735B2 (en) * 2006-10-31 2012-11-27 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
CA2703981A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Heterocyclic urea and thiourea derivatives and methods of use thereof
WO2009058730A1 (en) * 2007-10-29 2009-05-07 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
US8476278B2 (en) 2013-07-02
WO2009058728A1 (en) 2009-05-07
CN101910165A (zh) 2010-12-08
EP2212318B1 (en) 2013-07-24
PE20091347A1 (es) 2009-09-18
AR069083A1 (es) 2009-12-30
JP5230035B2 (ja) 2013-07-10
EP2212318A1 (en) 2010-08-04
CA2703978A1 (en) 2009-05-07
CL2008003200A1 (es) 2009-11-27
JP2011502156A (ja) 2011-01-20
US20100331313A1 (en) 2010-12-30
TW200930715A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
MX2009004791A (es) Derivados de anilinopiperazina t metodos de uso de los mismos.
MX2010004875A (es) Derivados de tiazol y metodos para utilizarlos.
MX2009004785A (es) Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
MX2009004786A (es) Derivados de anilinopiperazina y sus metodos de uso.
WO2011025706A3 (en) Heterocyclic amide compounds as protein kinase inhibitors
MX2010004878A (es) Derivados de tioeter y eter heterociclico y metodos de uso de los mismos.
MX2010004880A (es) Derivados heterociclicos de urea y tiourea, y metodos de uso de los mismos.
MX2010004876A (es) Derivados de diamido tiazol como inhibidores de la proteina cinasa.
WO2007149427A3 (en) Tyrosine kinase inhibitors
MY150032A (en) Heterocyclic amide compounds as protein kinase inhibitors
PH12018501976A1 (en) Arginase inhibitors and their therapeutic applications
WO2009011850A3 (en) Novel therapeutic compounds
TN2010000096A1 (en) Oxadiazole - and oxazole - substituted benzimidazole - and indole - derivatives as dgat1 inhibitors
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
EA200970738A1 (ru) Ингибиторы активности akt
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2007076161A3 (en) Compounds with therapeutic activity
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
IL195217A0 (en) Protein kinase inhibitors and uses thereof
EA201190140A1 (ru) Производные циклопропиламида, направленно действующие на гистаминовый н3-рецептор